Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
株価
$0.25974701
最終同期: 2025-01-06
時価総額
$2.04M
変化(1日)
0.74%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)の発行済株式数
June 2024 時点の発行済株式数 15.76M
Acticor Biotech SAS の最新の財務報告および株価によると、現在の発行済株式数は 15.76M です。December 2022 の終わりには、同社は 10.55M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Acticor Biotech SAS(ALACT)の発行済株式数の履歴(2010 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
2026 (TTM) 15.76M 30.55%
2023 12.07M 14.44%
2022 10.55M 35.54%
2021 7.78M 22.37%
2020 6.36M 21.38%
2019 5.24M 70.67%
2018 3.07M -7.38%
2017 3.31M 0.00%
2016 3.31M 0.00%
2015 3.31M 0.00%
2014 3.31M 0.00%
2013 3.31M 0.71%
2012 3.29M 0.00%
2011 3.29M -34.01%
2010 4.99M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数
253.90M 1,511.53%
US
62.19M 294.70%
NL
478.91M 2,939.70%
AU
396.00M 2,413.45%
US
- -
CH